Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SC79 是一个 AKT 激动剂,具有特异性和血脑屏障渗透性。SC79 可以特异性结合 AKT 的 PH 结构域,激活胞质中 AKT,并抑制 AKT 膜转位。SC79 具有神经保护活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 215 | 现货 | ||
5 mg | ¥ 472 | 现货 | ||
10 mg | ¥ 763 | 现货 | ||
25 mg | ¥ 1,380 | 现货 | ||
50 mg | ¥ 2,320 | 现货 | ||
100 mg | ¥ 3,480 | 待询 | ||
200 mg | ¥ 4,730 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 472 | 现货 |
产品描述 | SC79 is an AKT agonist with specificity and blood-brain barrier permeability. SC79 specifically binds to the PH domain of AKT, activates cytoplasmic AKT, and inhibits AKT membrane translocation. SC79 has neuroprotective activity. |
体外活性 |
方法:人宫颈癌细胞 HeLa 血清饥饿 1 h,用 SC79 (4 µg/mL) 处理 30 min,使用 Western Blot 检测靶点蛋白表达水平。 结果:SC79 增强了 AKT 磷酸化,SC79 诱导的 AKT 磷酸化主要发生在胞质中。[1] 方法:人肺癌细胞 A549 用 SC79 (10 µg/mL) 处理 24 h,使用 qPCR 检测基因表达水平。 结果:SC79 处理上调了 Nrf-2 (NFE2L2) 基因本身以及下游靶标 HO-1 和 NQO-1 的表达。[2] |
体内活性 |
方法:为检测体内活性,将 SC79 (0.04 mg/g) 腹腔注射给 C57 Black/6 小鼠铜松脱髓鞘模型,5 min 后进行大脑中动脉闭塞 (MCAO) 构建缺血性中风模型。 结果:单次剂量的 SC79 在 MCAO 后 24 h 和 MCAO 后 1 周将新皮质病变的大小分别减少 35% 和 40% 以上。[1] 方法:为研究对肝损伤的作用,将 SC79 (10 mg/kg) 腹腔注射给 C57BL/6 小鼠,0.5 h 后注射 d-Gal/LPS 诱导肝损伤。 结果:SC79 保护小鼠免受 d-Gal/LPS 诱导的 TNF-α 介导的肝损伤。[3] |
激酶实验 | Cytosolic phosphorylation of Akt: Hela cells are serum starved for 1 hr and treated with IGF (100ng/mL) or SC79 (4 μg/mL) for 30 minutes. Cells are lysed in Lysis buffer containing 250 mM Sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA supplemented with protease inhibitors. Cells are passed through 25 g needle several times and kept on ice for 20 minutes. Total cell lysate is taken at this point. Cell lysates are centrifuged at 100,000 g for 30 minutes. Supernatant is collected as the cytosolic fraction. Pellet is washed with lysis buffer and represents the membrane fraction. Total cell lysate, cytosolic and membrane fractions are resolved by SDS-PAGE and analyzed for phospho-Akt (S473), Total Akt, Tubulin (cytosolic marker) and Orai1 (membrane marker) by western blotting. |
细胞实验 | HsSultan or NB4 cells (2.5 × 105) are plated in a 24-well plate in 500 μL of phenol red-free RPMI medium supplemented with 10% FBS. After incubation for 24 hours, each compound (8 μg/mL) is added and cultured for overnight (16–20 h). Fifty microliters of MTT solution (5 mg/mL in PBS) are added to each well. Following 2 hrs incubation, the purple formazan crystals are dissolved by directly adding in 500 μL of isopropanol with 0.1 M HCl to each well. After clearing the cell debris by centrifugation, the absorbance is measured at a wavelength of 570 nm.(Only for Reference) |
别名 | SC 79, 2-氨基-6-氯-alpha-氰基-3-(乙氧羰基)-4H-1-苯并吡喃-4-乙酸乙酯 |
分子量 | 364.78 |
分子式 | C17H17ClN2O5 |
CAS No. | 305834-79-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 36.5 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7414 mL | 13.7069 mL | 27.4138 mL | 68.5345 mL |
5 mM | 0.5483 mL | 2.7414 mL | 5.4828 mL | 13.7069 mL | |
10 mM | 0.2741 mL | 1.3707 mL | 2.7414 mL | 6.8534 mL | |
20 mM | 0.1371 mL | 0.6853 mL | 1.3707 mL | 3.4267 mL | |
50 mM | 0.0548 mL | 0.2741 mL | 0.5483 mL | 1.3707 mL | |
100 mM | 0.0274 mL | 0.1371 mL | 0.2741 mL | 0.6853 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SC79 305834-79-1 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt SC 79 inhibit 2-氨基-6-氯-alpha-氰基-3-(乙氧羰基)-4H-1-苯并吡喃-4-乙酸乙酯 Protein kinase B Inhibitor SC-79 PKB inhibitor